Cash from Operations (Quarterly) Chart

Historical Cash from Operations (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
September 30, 2026 -5.516M
June 30, 2026 -8.666M
March 31, 2026 -5.782M
December 31, 2025 -6.674M
September 30, 2025 -4.298M
June 30, 2025 -7.211M
March 31, 2025 -7.58M
December 31, 2024 -7.927M
September 30, 2024 -8.863M
June 30, 2024 -10.18M
March 31, 2024 -10.58M
December 31, 2023 -8.106M
September 30, 2023 -9.687M
June 30, 2023 -12.06M
March 31, 2023 -17.57M
December 31, 2022 -10.48M
September 30, 2022 -10.33M
June 30, 2022 -8.148M
March 31, 2022 -3.515M
December 31, 2021 -8.598M
September 30, 2021 -4.964M
June 30, 2021 -4.538M
March 31, 2021 -5.475M
December 31, 2020 -6.302M
September 30, 2020 -3.88M
Date Value
June 30, 2020 -3.856M
March 31, 2020 -4.232M
December 31, 2019 -2.729M
September 30, 2019 -4.567M
June 30, 2019 -5.827M
March 31, 2019 -2.459M
December 31, 2018 -3.195M
September 30, 2018 -2.02M
June 30, 2018 -1.876M
March 31, 2018 -3.536M
December 31, 2017 -2.369M
September 30, 2017 -0.593M
June 30, 2017 -2.931M
March 31, 2017 -3.299M
December 31, 2016 -1.481M
September 30, 2016 -3.131M
June 30, 2016 -2.892M
March 31, 2016 -3.085M
December 31, 2015 -2.317M
September 30, 2015 -2.497M
June 30, 2015 -2.662M
March 31, 2015 -2.305M
December 31, 2014 -3.20M
September 30, 2014 -2.627M
June 30, 2014 -3.058M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (Quarterly) Range, Past 5 Years

View Cash from Operations (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (Quarterly) Benchmarks

View Cash from Operations (Quarterly) Benchmarks
Start Trial
Lineage Cell Therapeutics, Inc. -5.62M
Voyager Therapeutics, Inc. -19.67M
Black Diamond Therapeutics, Inc. -8.338M
Invivyd, Inc. -32.11M
Elicio Therapeutics, Inc. -10.36M